

## Facts & Figures

- IAVI is a global not-for-profit, public-private partnership working to accelerate the development of a vaccine to prevent HIV infection and AIDS.
- IAVI is the world's only organization focused solely on developing an AIDS vaccine.
- Founded in 1996, IAVI researches and develops vaccine candidates, conducts policy analyses and serves as an advocate for the field. It also works to ensure a future vaccine will be accessible to all who need it.
- IAVI supports a comprehensive approach to HIV/AIDS that balances the expansion and strengthening of existing HIV prevention and treatment programmes with targeted investments in new AIDS prevention technologies.
- IAVI's staff of approximately 200 people and its partners are active in 24 countries (Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Ireland, India, Italy, Japan, Kenya, Netherlands, Norway, Rwanda, South Africa, Spain, Sweden, Switzerland, Uganda, United Kingdom, United States and Zambia).
- IAVI has offices in five countries: United States/New York (Headquarters), Netherlands/Amsterdam (Europe Office); India/New Delhi (India Office), Kenya/Nairobi (Eastern African Office), and South Africa/Johannesburg (Southern Africa Office).

## IAVI discovers

- IAVI researches and develops AIDS vaccine candidates and conducts clinical trials and clinical research through partnerships with more than 40 academic, biotechnology, pharmaceutical and government institutions.
- In the last six years, IAVI and its network of partners have translated innovative technologies into six vaccine candidates that have entered human trials in 11 countries in Asia, Africa, Europe and North America.

## IAVI partners

- IAVI's AIDS vaccine trials, conducted in collaboration with local scientists, are located primarily in Africa and India, where different subtypes of the virus are circulating.
- In other areas of the world where IAVI is not currently sponsoring AIDS vaccine trials – Brazil and China, for example – the organization works with on-the-ground partners to support national efforts in HIV vaccine research and mobilization.
- IAVI partners with developing-country stakeholders – including researchers, policymakers and community and women's health organizations.

### **IAVI advocates**

- IAVI's policy programme works to analyze how improved public policies could help to accelerate vaccine R&D and ensure rapid global access to a future vaccine.
- IAVI's advocacy programme builds on policy analysis to promote awareness among political, community, financial and scientific leaders about the urgent need for an AIDS vaccine.

### **IAVI mobilizes**

- IAVI is supported by governments, foundations, charities, multilateral organizations, corporate and private donors, and many generous individuals worldwide
- As of January, 2007, and since its inception in 1996, IAVI has mobilized more than US\$583m to accelerate the search for an AIDS vaccine.

'Improving access to medicines will continue to require a global effort involving governments, the pharmaceutical industry and civil society. At the same time, we must strengthen long-term research into a preventative vaccine. That is why the UK supports the International Aids Vaccine Initiative, a public-private partnership that has already enabled the development of several candidate vaccines.'

Gordon Brown, Chancellor of the Exchequer (UK), The Independent (UK), 1 December 2006